. Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Stu J Clin Oncol 2024 Nov 19:JCO2402470. doi: 10.1200/JCO-24-02470.
PMID: 39561315